Lung Cancer: Symptoms, Risk Factors and How It Is Detected Early

Lung cancer is often associated with severe coughing or coughing up blood, but early lung cancer may cause no obvious symptoms at all. At the same time, a persistent cough does not automatically mean cancer because many respiratory conditions can produce similar symptoms.[1][2]

This is why lung cancer screening in people without symptoms but at increased risk is very different from diagnostic evaluation in someone who already has suspicious symptoms or an abnormal scan.

When lung cancer is suspected, the process also extends beyond seeing a mass on a scan. Tissue may be needed to determine the cancer type, followed by staging and, in many cases, biomarker testing that can significantly affect treatment selection.[2][8]

What Is Lung Cancer?

Lung cancer develops when abnormal cells arising in lung tissue grow uncontrollably.

It is not one single disease. Two major categories are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which differ in their biology, pattern of spread, and treatment.[2][3]

Once cancer is diagnosed, treatment depends on factors including cancer type, stage, general health, and in some cases the molecular characteristics of the tumor.

Does Lung Cancer Cause Symptoms in Its Early Stages?

Not always.

Lung cancer can develop without clear early symptoms and may sometimes be discovered incidentally on chest imaging performed for another reason or through screening in a higher-risk person.[2]

However, this does not mean that everyone without symptoms should undergo CT screening. Screening has demonstrated benefit when it is targeted to populations whose lung cancer risk is high enough to outweigh the potential harms.[5]

What Are the Symptoms of Lung Cancer?

Possible symptoms include:[1][3]

• A new cough that does not go away.
• A long-standing cough that changes or worsens.
• Shortness of breath.
• Blood in sputum.
• Chest pain or discomfort.
• Hoarseness.
• Wheezing in some patients.
• Loss of appetite.
• Unexplained weight loss.
• Persistent fatigue.
• Difficulty swallowing in some cases.
• Swelling of the face or neck in some advanced cases.

Cancer that has spread beyond the lung may produce symptoms related to other areas, such as bone pain or neurological symptoms.

When Is a Cough Concerning?

A cough is common and highly nonspecific, but assessment becomes particularly important when a cough:

• Persists rather than improving.
• Represents a clear change in a smoker's usual chronic cough.
• Becomes progressively more frequent or severe.
• Is accompanied by blood in sputum.
• Occurs with persistent chest pain or unexplained breathlessness.
• Occurs with unexplained weight or appetite loss.
• Is associated with recurrent pneumonia in the same area.

The goal is not to interpret every cough as cancer, but to investigate a persistent or changing symptom rather than ignoring it.

What Increases the Risk of Lung Cancer?

Smoking

Tobacco smoking is the most important modifiable risk factor for lung cancer.

Risk rises with both the amount smoked and the number of years of smoking. Quitting reduces lung cancer risk compared with continuing to smoke.[4]

Secondhand smoke

Regular exposure to other people's tobacco smoke is also an established lung cancer risk factor.[4]

Radon

Radon is a naturally occurring radioactive gas that can accumulate in buildings and is an established lung cancer risk factor, particularly in combination with smoking.[4]

Occupational exposure

Risk is associated with workplace exposure to carcinogens such as:

• Asbestos.
• Arsenic.
• Chromium.
• Nickel.
• Beryllium.
• Cadmium.
• Tar and soot.[4]

Air pollution and radiation exposure

Outdoor air pollution and some types of radiation exposure are also associated with increased lung cancer risk.[4]

Age and family history

Risk generally increases with age, and a family history of lung cancer can also be associated with higher risk.

Can People Who Have Never Smoked Develop Lung Cancer?

Yes.

Smoking remains the major risk factor, but it is not a requirement for developing lung cancer.

Lung cancer in never-smokers can be associated with factors including secondhand smoke, radon, occupational and environmental exposures, radiation, and family history.[4]

Persistent respiratory symptoms therefore should not be dismissed solely because a person has never smoked.

What Are the Main Types of Lung Cancer?

What Is the Difference Between Lung Cancer Screening and Diagnosis?

Who May Need Low-Dose CT Lung Cancer Screening?

Lung cancer screening is not recommended indiscriminately for all adults.

The current Saudi Health Council page describes annual low-dose CT screening for selected long-term smokers aged 50 to 80 years, using a high cumulative smoking-exposure threshold and considering people who quit within the previous 15 years.[1]

International recommendations differ in some details.

The USPSTF recommends annual LDCT for adults aged 50 to 80 years with at least a 20 pack-year smoking history who currently smoke or quit within the past 15 years.[6]

The American Cancer Society also uses age 50 to 80 years and at least 20 pack-years but no longer uses years since quitting as an eligibility requirement.[7]

These differences are one reason screening eligibility should be assessed according to the relevant health program and individual clinical circumstances rather than applying one rule universally.

What is a pack-year?

One pack-year means smoking an average of one pack of cigarettes per day for one year.

For example, one pack per day for 20 years equals 20 pack-years, while two packs per day for 10 years also equals approximately 20 pack-years.

Can a regular chest X-ray be used instead?

Chest X-ray is not an equivalent substitute for LDCT screening in high-risk populations.

Randomized screening evidence has shown a mortality benefit with LDCT, whereas chest X-ray screening has not produced the same reduction in lung cancer mortality.[5]

Does LDCT screening have downsides?

Yes. Screening can identify nodules and abnormalities that are not cancer, resulting in follow-up scans and occasionally invasive testing.

Other potential harms include radiation exposure, incidental findings, anxiety, and overdiagnosis.[5]

A separate guide will cover lung cancer screening eligibility, LDCT, pack-years, benefits, and harms in detail.

How Is Lung Cancer Diagnosed?

There is no single test that answers every question about suspected lung cancer.

The pathway may involve:

Medical history and examination

Clinicians consider symptoms, smoking history, occupational and environmental exposures, family history, and overall health.

Imaging

CT imaging can identify the size, location, and characteristics of an abnormality and whether lymph nodes or surrounding structures appear involved.

However, an abnormality on CT is not automatically cancer.

Tissue sampling

Tissue can be obtained using methods such as:

• Bronchoscopy.
• Image-guided needle biopsy.
• Lymph-node biopsy.
• Surgical biopsy in selected cases.[2]

The Pulmonology Department at Mouwasat Hospital evaluates lung conditions and includes interventional pulmonary expertise and bronchoscopic biopsy services among its published capabilities.

Can a Scan Alone Confirm Lung Cancer?

Usually not.

Imaging can make an abnormality more or less suspicious, but a biopsy is often required to confirm cancer and determine the exact histologic type.[8]

This matters because infections, inflammatory changes, scarring, and benign pulmonary nodules can sometimes resemble cancer on imaging.

How Is Lung Cancer Staged?

After diagnosis, clinicians determine how far the disease has spread because stage has major treatment and prognostic implications.

For NSCLC, staging considers the primary tumor, lymph nodes, and whether cancer has spread to distant sites.[2]

Staging investigations may include:

• CT.
• PET/CT.
• Brain MRI in appropriate patients.
• Sampling of lymph nodes or other suspicious areas.

Small cell lung cancer follows a somewhat different clinical staging and treatment framework because of its faster pattern of spread.[3]

A separate guide will explain lung cancer stages and what stages I through IV mean for treatment and prognosis.

Why Is Biomarker Testing Important in Lung Cancer?

Biomarker testing has transformed the treatment of many patients with lung cancer.

In some NSCLC tumors, molecular testing can identify alterations that have treatments specifically designed to target them.

EGFR is one example, while other molecular and immune biomarkers may also be tested depending on the tumor type and clinical setting.[9]

Results can help determine:

• Whether a targeted therapy may be appropriate.
• Whether certain immunotherapies may be useful.
• Which treatment strategy best matches the biology of the cancer.

How Is Lung Cancer Treated?

Treatment can include one or more approaches depending on lung cancer type, stage, tumor biology, and overall health.

Surgery

Surgery can be important for selected patients with localized, resectable NSCLC. Procedures may include wedge resection, segmentectomy, or lobectomy depending on the tumor and lung function.[2]

The Chest Surgery Department at Mouwasat Hospital provides surgical evaluation and management of lung lesions and lung cancer, including minimally invasive approaches in appropriate patients.

Radiation therapy

Radiotherapy may be used with curative intent in some settings, together with other treatments, or to control specific areas of disease and symptoms.

Chemotherapy

Chemotherapy remains an important treatment for several lung cancer types and stages and may be combined with surgery, radiation, immunotherapy, or other systemic treatments.

Targeted therapy

Targeted therapy is selected when a tumor has a biomarker that can be matched to an available treatment.[9]

Immunotherapy

Immune-based therapy can be appropriate for selected patients depending on cancer type, stage, biomarkers, previous treatments, and other factors.

The Oncology Department at Mouwasat Hospital lists care for both small-cell and non-small-cell lung cancer, including chemotherapy, targeted therapy, immunotherapy, and multidisciplinary treatment.

Can Lung Cancer Be Cured?

Some lung cancers can be treated with curative intent, particularly when disease is localized and suitable for definitive treatment.

The chance of long-term disease control or cure depends on factors including:

• Lung cancer type.
• Stage at diagnosis.
• Whether the tumor can be treated definitively with surgery or other local therapy.
• Tumor biology and biomarkers.
• Response to treatment.
• Overall health.

For advanced lung cancer, treatment may instead focus on controlling the disease for as long as possible, relieving symptoms, and maintaining quality of life.

Statements such as “stage IV lung cancer cannot be treated” or “a particular therapy cures all lung cancer” are therefore both misleading simplifications.

When Should You See a Doctor?

Medical assessment is particularly important for:

• A persistent or worsening cough.
• A clear change in a longstanding cough.
• Blood in sputum.
• Unexplained or progressive breathlessness.
• Persistent chest pain.
• Persistent unexplained hoarseness.
• Unexplained weight or appetite loss.
• Repeated chest infections or pneumonia that does not resolve as expected.

Lung Cancer Care at Mouwasat Hospital

Lung cancer care often requires several specialties working together.

The Pulmonology Department provides respiratory assessment and diagnostic procedures, including interventional pulmonology capabilities in selected locations.

When cancer is confirmed, the Oncology Department contributes systemic cancer treatment including chemotherapy, targeted therapy, and immunotherapy according to the individual case.

If surgical treatment is appropriate, the Chest Surgery Department evaluates options for lung resection and other thoracic procedures.

The final treatment plan depends on pathology, stage, tumor biomarkers, lung function, overall health, and patient-specific circumstances rather than any single scan or test.

Frequently Asked Questions About Lung Cancer

What are the first symptoms of lung cancer?

There is no single first symptom, and early lung cancer may cause no obvious symptoms. Possible signs include a persistent or changing cough, shortness of breath, chest discomfort, or blood in sputum.

Does lung cancer always cause coughing?

No. Some patients have no significant cough, especially early in the disease, and most coughs are caused by conditions other than cancer.

What does a lung cancer cough feel like?

There is no specific cough pattern that proves cancer. A new persistent cough or a change in a longstanding cough deserves greater attention, especially when accompanied by blood, unexplained weight loss, chest pain, or breathlessness.

Does blood in sputum mean lung cancer?

No. Infections and other lung diseases can also cause hemoptysis, but coughing up blood should be medically evaluated.

Can a nonsmoker get lung cancer?

Yes. Lung cancer can occur in people who have never smoked. Secondhand smoke, radon, occupational carcinogens, radiation, and other factors can contribute to risk.[4]

Can a chest X-ray detect lung cancer?

A chest X-ray can sometimes show an abnormality, but it is not the recommended substitute for LDCT screening in eligible high-risk individuals and cannot by itself confirm cancer.

Can CT confirm lung cancer?

No. CT can identify a suspicious mass or nodule, but tissue biopsy is commonly needed to confirm cancer and determine its type.[8]

Does every lung nodule mean cancer?

No. Many pulmonary nodules are benign. Their significance depends on factors such as size, appearance, growth over time, and individual cancer risk.

Does lung cancer spread quickly?

It depends on the type. Small cell lung cancer generally grows and spreads more rapidly than many non-small cell lung cancers.[3]

Can lung cancer be cured?

Some cases can be treated with curative intent, particularly when disease is detected at a localized stage. Treatment goals and outcomes vary substantially in advanced disease.

Can a blood test diagnose lung cancer?

No routine blood test alone can reliably confirm or exclude lung cancer. Diagnosis usually combines clinical assessment, imaging, and tissue evaluation.

Who should be screened for lung cancer?

Screening is recommended for selected higher-risk people based largely on age and cumulative smoking history. Exact eligibility criteria vary among guidelines and health programs.

Is it still worth quitting smoking after many years?

Yes. Quitting smoking reduces lung cancer risk compared with continuing to smoke and provides many additional health benefits.[4]

Final Thoughts: Early Detection Is Not the Same as Waiting for Symptoms

One of the most important misconceptions about lung cancer is that it must cause an obvious cough or severe symptoms before it can be found.

Lung cancer may be silent early, which is why screening exists for selected higher-risk people. At the same time, screening is not appropriate for everyone, and a person who already has concerning symptoms needs diagnostic evaluation rather than simply requesting a screening scan.

Once a suspicious lung abnormality is found, the clinically important questions become more specific: Is it cancer? What type is it? What stage is it? Does it have an actionable biomarker?

Those answers, rather than the scan alone, determine the most appropriate treatment pathway.

Medical disclaimer: This article is intended for general health education and does not replace medical assessment, particularly when coughing up blood, progressive breathlessness, persistent cough, or unexplained weight loss is present.

Medical References

1. Saudi Health Council — Lung Cancer
2. National Cancer Institute — Non-Small Cell Lung Cancer Treatment
3. National Cancer Institute — Small Cell Lung Cancer Treatment
4. National Cancer Institute — Lung Cancer Prevention and Risk Factors
5. National Cancer Institute — Lung Cancer Screening
6. U.S. Preventive Services Task Force — Lung Cancer Screening Recommendation
7. American Cancer Society — Lung Cancer Screening Guideline
8. National Cancer Institute — How Cancer Is Diagnosed
9. National Cancer Institute — Biomarker Testing for Cancer Treatment

Lung Cancer Screening: Who Should Have a Low-Dose CT Scan?

Having a CT scan “just to be safe” may sound reasonable, especially for someone with a long smoking history. However, lung cancer screening is not recommended for everyone and is not simply a CT scan offered to anyone worried about cancer.

Screening is designed primarily for people who do not have concerning symptoms but whose risk of lung cancer is high enough that early detection may provide a meaningful benefit.

Someone who is already coughing up blood, experiencing a concerning persistent cough, or developing other suspicious symptoms needs diagnostic evaluation rather than routine screening.

The test shown to reduce lung-cancer mortality in appropriately selected higher-risk populations is low-dose computed tomography, or LDCT, not a routine chest X-ray.[1][2]

What Is Lung Cancer Screening?

Lung cancer screening means testing a person who does not currently have suspicious symptoms but has a sufficiently increased risk of developing lung cancer.

The goal is to identify some lung cancers at an earlier stage, when treatment may be more effective.

Large randomized studies have shown that LDCT screening in appropriately selected high-risk populations can reduce deaths from lung cancer compared with chest X-ray or no screening.[2]

What Is the Difference Between Screening and Diagnostic Evaluation?

For example, a long-term smoker who feels well may be eligible to discuss screening.

A person who is coughing up blood should not wait for a screening appointment; that symptom requires diagnostic assessment.

Who Should Be Screened for Lung Cancer?

Age and cumulative cigarette exposure are the main factors used by major screening guidelines.

However, the exact eligibility rules are not identical across organizations.

Screening should therefore be based on the relevant national or clinical program and the individual's health rather than assuming that one international threshold applies universally.

What Does Current Saudi Guidance Say?

The current Saudi Health Council page describes annual LDCT screening for long-term smokers aged 50 to 80 years.[1]

It gives examples of heavy cumulative smoking exposure including:

• At least one pack per day for 30 years or more.
• Two packs per day for 15 years or more.

Both examples are equivalent to approximately 30 pack-years.

The page also includes people who stopped smoking within the previous 15 years.[1]

Why Do Lung Cancer Screening Guidelines Differ?

These differences reflect how organizations weigh benefits and harms and how their recommendations are intended to be implemented.

How Do You Calculate Pack-Years?

A pack-year is a way of measuring cumulative cigarette exposure.

USPSTF defines one pack-year as the equivalent of smoking approximately one pack, or 20 cigarettes, per day for one year.[3]

What Is Low-Dose CT?

Low-dose computed tomography is a CT technique designed to image the lungs using less radiation than many standard diagnostic chest CT examinations.

Screening LDCT usually does not require intravenous contrast.

Its purpose is to identify small pulmonary abnormalities that may warrant monitoring or further investigation rather than to provide a final cancer diagnosis by itself.

Can a Chest X-Ray Be Used Instead?

No.

Chest X-rays can reveal some lung abnormalities, but they are not an equivalent substitute for LDCT screening.

NCI reports that screening with chest X-ray or sputum cytology did not reduce the risk of dying from lung cancer, whereas LDCT demonstrated a mortality benefit in appropriately selected high-risk populations.[2]

What Are the Benefits of LDCT Screening?

The main benefit is earlier detection of some lung cancers before symptoms develop or disease becomes advanced.

Large randomized trials have shown a meaningful reduction in lung cancer mortality among appropriately selected high-risk people screened with LDCT.[2][5]

This does not mean screening prevents lung cancer or detects every cancer.

What Are the Potential Harms of LDCT Screening?

Screening has important limitations.

False-positive findings

LDCT can detect many abnormalities that are not cancer.

Large trials have reported substantial false-positive rates, and some patients consequently undergo repeat imaging or invasive diagnostic procedures for abnormalities that later prove benign.[5]

Radiation exposure

LDCT uses less radiation than a typical diagnostic chest CT but still involves ionizing radiation, particularly relevant when screening is repeated annually.

Overdiagnosis

Screening can occasionally detect a cancer that would not have caused symptoms or death during the person's lifetime, potentially resulting in unnecessary treatment.

Incidental findings

The scan can identify unrelated abnormalities in the lungs, heart, or other structures that may require further assessment.

Anxiety

An indeterminate nodule and the need to wait for follow-up imaging can also cause significant anxiety.

Does a Lung Nodule Mean Cancer?

No.

Many pulmonary nodules are benign and can result from old infection, inflammation, scarring, or other noncancerous causes.

Evaluation considers factors such as:

• Nodule size.
• Shape and margins.
• Whether it is solid or has another appearance.
• Growth over time.
• Age.
• Smoking history.
• Other cancer risk factors.

For some nodules, the safest next step is simply another scan after a defined interval rather than immediate biopsy.

What Happens After an Abnormal LDCT?

The next step depends on how suspicious the finding appears.

Management may involve:

• Repeat LDCT after a specified interval.
• A diagnostic chest CT.
• PET/CT in selected cases.
• Pulmonology assessment.
• Bronchoscopy.
• Biopsy when the probability of cancer justifies tissue sampling.

At this point, the process has moved from screening into diagnostic evaluation.

When Should Lung Cancer Screening Stop?

According to USPSTF, annual screening should stop when a person:

• Exceeds the recommended age range.
• Has not smoked for 15 years under the USPSTF framework.
• Develops a health condition that substantially limits life expectancy.
• Is unable or unwilling to undergo curative lung surgery if cancer is found.[3]

The American Cancer Society no longer uses years since quitting as an eligibility cutoff, highlighting another important difference between screening recommendations.[4]

The underlying principle is that screening is most valuable when finding cancer early can realistically lead to meaningful treatment benefit.

Does Screening Replace Smoking Cessation?

No.

LDCT screening can reduce lung cancer mortality among eligible high-risk people, but it does not prevent the ongoing harmful effects of tobacco exposure.

USPSTF specifically recommends smoking-cessation interventions for current smokers participating in screening programs.[3]

Lung Cancer Risk Assessment at Mouwasat Hospital

People with a significant smoking history or concerns about lung health can discuss their symptoms and risk factors with the Pulmonology Department at Mouwasat Hospital.

The department's published services include lung cancer diagnosis and staging in collaboration with Oncology, bronchoscopy with biopsy, and navigational bronchoscopy in appropriate patients.[6]

This does not establish that a dedicated LDCT lung cancer screening program is available at every Mouwasat location. Availability of the appropriate scan and screening pathway should be confirmed for the relevant hospital and individual situation.

Frequently Asked Questions About Lung Cancer Screening

Should every smoker have a yearly CT scan?

No. Eligibility depends on age, cumulative smoking exposure, time since quitting, overall health, and the screening guideline being used.

I have smoked for 20 years. Do I need LDCT?

The number of years alone is not enough. The average number of cigarettes smoked per day must also be considered to calculate pack-years.

What does 20 pack-years mean?

Examples include one pack per day for 20 years, half a pack per day for 40 years, or two packs per day for 10 years.

Does shisha smoking count as pack-years?

Pack-years were developed primarily for cigarette smoking, and there is no simple universally accepted conversion of shisha exposure into cigarette pack-years. Shisha use should still be reported when assessing lung cancer risk.

Does vaping make someone eligible for lung cancer screening?

Current screening eligibility criteria are based mainly on conventional cigarette smoking history. There is no established pack-year conversion for exclusive e-cigarette use, so risk should be assessed individually.

Can a chest X-ray screen for lung cancer?

It can detect some abnormalities, but it is not an equivalent substitute for LDCT screening and has not demonstrated the same reduction in lung cancer mortality.[2]

Does LDCT require contrast dye?

Routine LDCT used for lung cancer screening generally does not require intravenous contrast.

Is LDCT painful?

No. The scan itself is painless and takes only a short time while the patient lies on the CT table.

Is low-dose CT safe?

It uses less radiation than many standard diagnostic CT examinations, but radiation exposure is not zero. This is why screening is targeted to people expected to gain a meaningful benefit.

Does finding a lung nodule mean I have cancer?

No. Many lung nodules are benign, and some only require follow-up imaging.

Should a nonsmoker have LDCT just for reassurance?

Routine LDCT screening is not recommended for all nonsmokers simply for reassurance. Symptoms or other risk factors may justify clinical assessment, but that is different from population screening.

If I have lung cancer symptoms, should I request a screening LDCT?

Concerning symptoms require diagnostic evaluation rather than relying on screening eligibility criteria.

How often is lung cancer screening performed?

Major LDCT screening recommendations generally use annual screening while the person continues to meet eligibility criteria.[1][3]

Final Thoughts: Effective Screening Starts With Selecting the Right Person

Early detection does not mean that CT screening should be performed indiscriminately.

LDCT can reduce lung cancer mortality when used in appropriately selected high-risk people, but it can also identify benign nodules and lead to repeat scans or additional procedures.

The decision therefore starts with three questions:

• Do I already have concerning symptoms? If so, diagnostic evaluation may be needed instead of screening.
• What are my age and cumulative smoking exposure in pack-years?
• Would my overall health allow me to benefit from early treatment if cancer were found?

That is the goal of good lung cancer screening: not simply finding more abnormalities, but finding clinically important disease early in people who are most likely to benefit.

Medical disclaimer: This article is intended for general health education and should not be used to determine lung cancer screening eligibility without individualized medical assessment. Concerning respiratory symptoms require diagnostic evaluation regardless of screening criteria.

Medical References

1. Saudi Health Council — Lung Cancer Screening and Early Detection
2. National Cancer Institute — Lung Cancer Screening
3. U.S. Preventive Services Task Force — Lung Cancer Screening
4. American Cancer Society — Lung Cancer Screening Guideline
5. National Cancer Institute — Lung Cancer Screening: Evidence, Benefits and Harms
6. Mouwasat Hospital — Pulmonology

Lung Cancer Treatment: How Doctors Choose Between Surgery, Targeted Therapy and Immunotherapy

Lung cancer treatment is no longer a simple choice between “surgery or chemotherapy.” Two people with apparently similar stages of lung cancer can receive very different treatment plans because of differences in cancer type, molecular features, resectability, overall health, lung function, and immune biomarkers.

Some patients with non-small cell lung cancer may begin with surgery, while others need systemic treatment before or after an operation. In advanced disease, an actionable molecular alteration can make targeted therapy a major treatment option, while other tumors may be better treated with immunotherapy, chemotherapy, or combinations of these treatments.[1][2]

The better question is therefore not “What is the strongest treatment for lung cancer?” but “Which treatment best matches this cancer, at this stage, in this particular patient?”

How Is Lung Cancer Treatment Selected?

Before choosing treatment, the cancer team needs to answer several questions:

• Is the cancer NSCLC or SCLC?
• What is the exact histologic subtype?
• What stage is the disease?
• Can the tumor be removed surgically?
• Are lymph nodes involved?
• Has cancer spread to distant organs?
• Are actionable molecular alterations present?
• What are relevant immune markers such as PD-L1 when indicated?
• What is the patient's performance status?
• Are lung and heart function adequate for surgery or other treatment?
• What are the goals and preferences of the patient?

NCI describes treatment selection in NSCLC as dependent on factors including histology, molecular features, tumor extent, lymph-node involvement, overall health, comorbidities, and performance status.[1][2]

Why Does NSCLC vs SCLC Matter?

How Does Lung Cancer Stage Affect Treatment?

Stage describes the extent of cancer and is one of the most important treatment variables.

NSCLC may be localized and resectable, locally advanced, or metastatic.

However, patients within the same broad stage can follow different treatment pathways.

For example, some stage III cancers can be approached with surgery within a multimodality plan, while others are unresectable and may be treated with chemotherapy and radiation followed by additional systemic therapy when appropriate.[1]

A separate guide in this series will explain stages I through IV and what they mean for treatment and prognosis.

When Is Surgery Used for Lung Cancer?

Surgery is an important potentially curative treatment for selected patients with localized, resectable NSCLC.

Procedures can include:

• Wedge resection — removal of the tumor with a small rim of surrounding lung.
• Segmentectomy — removal of an anatomical segment of the lung.
• Lobectomy — removal of an entire lung lobe.
• Sleeve resection — removal of involved airway tissue while preserving lung when appropriate.
• Pneumonectomy — removal of an entire lung in selected cases.[1]

The operation is selected according to tumor location, lymph-node status, pulmonary reserve, general health, and whether an adequate cancer resection can be achieved.

The Chest Surgery Department at Mouwasat Hospital lists lung cancer surgery including lobectomy, segmentectomy, wedge resection, and pneumonectomy among its published services, with minimally invasive techniques used in appropriate cases.[5]

Does Lung Cancer Treatment End After Surgery?

Not necessarily.

Modern treatment of resectable NSCLC may involve treatment before surgery, after surgery, or both.

Neoadjuvant therapy

Treatment given before surgery can address microscopic disease early and may improve cancer control.

Some current NSCLC strategies include chemotherapy combined with immunotherapy before surgery in selected patients.[1]

Adjuvant therapy

After resection, selected patients may receive:

• Chemotherapy.
• Immunotherapy.
• Targeted therapy when an appropriate molecular alteration is present.
• Radiation therapy in selected clinical situations.

This is why surgical planning ideally occurs as part of a multidisciplinary cancer strategy rather than as an isolated decision.

What Is the Role of Radiation Therapy?

Radiation therapy is not limited to end-stage cancer.

It can be used:

• With curative intent for selected early tumors when surgery is unsuitable.
• With chemotherapy in locally advanced disease.
• As part of treatment for SCLC.
• For selected sites of metastatic disease.
• To relieve symptoms such as pain or pressure.

In unresectable NSCLC, radiation can form part of a combined chemoradiation strategy followed by additional therapy when appropriate.[1]

Is Chemotherapy Still Important?

Yes.

The arrival of targeted therapy and immunotherapy has not made chemotherapy obsolete.

Chemotherapy remains important:

• Before surgery in selected NSCLC.
• After surgery in selected stages.
• With radiation therapy.
• With immunotherapy in many advanced NSCLC regimens.
• As a core component of SCLC treatment.

What Is Targeted Therapy for Lung Cancer?

Targeted therapy is designed to attack a specific molecular abnormality or biological pathway that helps cancer cells grow.

The key principle is:

Targeted therapy requires a relevant target.

Examples of potentially actionable alterations in NSCLC include:

• EGFR
• ALK
• ROS1
• BRAF V600E
• MET exon 14 skipping
• RET
• NTRK
• KRAS G12C
• Selected HER2 alterations and others depending on the clinical setting.[2]

Finding a matching biomarker does not guarantee that a targeted therapy will work indefinitely. Tumors can vary biologically and may develop resistance over time.[4]

Why Is Biomarker Testing Important?

Biomarker testing looks for characteristics of the tumor that can help predict which treatments may be useful.

Testing is commonly performed on tumor tissue, although other molecular techniques may be used in selected situations.

In advanced NSCLC, NCI identifies molecular alterations and immune features such as PD-L1 expression as critical factors in treatment selection.[2]

Testing can help answer questions such as:

• Is there an actionable molecular alteration?
• Could targeted therapy be appropriate?
• Does the immune profile support a particular immunotherapy strategy?
• Should chemotherapy be combined with immunotherapy?

What Is Immunotherapy?

Immunotherapy helps the immune system recognize and attack cancer more effectively.

Immune checkpoint inhibitors are used in multiple NSCLC and SCLC treatment settings.[1][3]

Immunotherapy may be used:

• With chemotherapy.
• Alone in selected patients.
• Before surgery in certain resectable cancers.
• After surgery or after chemoradiation in selected settings.

PD-L1 can help guide some immunotherapy decisions, but it is not the only factor. The presence of a targetable driver alteration can substantially change the preferred treatment sequence.

How Is Stage IV Lung Cancer Treated?

Stage IV means that cancer has spread beyond its original lung site to a distant location.

For metastatic NSCLC, treatment generally aims to:

• Prolong survival.
• Control disease for as long as possible.
• Relieve symptoms.
• Maintain or improve quality of life.

Treatment options can include:

• Targeted therapy for an actionable alteration.
• Immunotherapy.
• Chemotherapy.
• Chemotherapy combined with immunotherapy.
• Radiation or other local treatment for selected disease sites.
• Supportive and palliative care alongside cancer-directed therapy.

NCI notes that stage IV NSCLC treatment selection depends on histology, molecular and immune features, comorbidities, age, and performance status.[2]

Does stage IV mean there is no treatment?

No.

Modern systemic treatments can produce significant and sometimes long-lasting responses in selected patients, particularly when a highly effective targeted treatment matches the tumor biology or when the cancer responds well to immunotherapy.

However, these outcomes vary substantially and should not be described as a guaranteed cure.

A published Mouwasat Hospital Madinah case describes a patient with stage IV lung cancer whose tumor biopsy and genetic and immune testing identified a targetable alteration. A multidisciplinary team developed a plan involving targeted therapy, chemotherapy, and radiation, followed by a major sustained clinical improvement.[8]

The case illustrates the value of molecular testing and multidisciplinary care; it does not predict the outcome of every patient with stage IV lung cancer.

How Is Small Cell Lung Cancer Treated?

SCLC tends to grow and spread faster than many non-small cell lung cancers.

In limited-stage disease, treatment commonly relies on:

• Chemotherapy.
• Thoracic radiation therapy.
• Immunotherapy in selected current treatment settings.

Extensive-stage disease is generally treated primarily with systemic therapy, including chemotherapy and immunotherapy in appropriate patients.[3]

Surgery has a much smaller role than in NSCLC and is considered only in carefully selected very early cases.

Why Does Performance Status Matter?

Cancer treatment is chosen for a patient, not for a scan.

Performance status describes how well a person can perform daily activities and care for themselves.

Treatment planning also considers:

• Lung function.
• Cardiac health.
• Kidney and liver function.
• Comorbidities.
• Other medications.
• Symptoms and disease burden.
• Overall treatment tolerance.

NCI lists age, comorbidities, and performance status among important factors affecting treatment selection in advanced NSCLC.[2]

What Is the Role of Supportive and Palliative Care?

Palliative care does not mean stopping cancer treatment or “giving up.”

Supportive and palliative treatment can be provided alongside cancer-directed therapy to manage:

• Pain.
• Shortness of breath.
• Cough.
• Fatigue.
• Nausea and treatment side effects.
• Loss of appetite or weight.
• Anxiety and emotional distress.

Radiation and other procedures may also be used to control a troublesome disease site even when the objective is symptom control rather than complete eradication of cancer.

Can Lung Cancer Be Cured?

Some lung cancers can be treated with curative intent, especially when disease is localized and suitable for definitive surgery, radiation, or multimodality therapy.

The possibility of cure or long-term disease control depends on:

• Cancer type.
• Stage.
• Resectability.
• Presence of distant metastases.
• Tumor biomarkers.
• Response to treatment.
• Overall health.

For metastatic cancer, treatment usually focuses on long-term disease control, survival, symptom relief, and quality of life, although some patients can experience prolonged responses to modern treatments.

What Does the Treatment Decision Look Like in Practice?

Lung Cancer Treatment at Mouwasat Hospital

Published Mouwasat services demonstrate a multidisciplinary lung cancer pathway across several specialties.

The Pulmonology Department lists lung cancer diagnosis and staging in collaboration with Oncology, as well as bronchoscopy with biopsy and navigational bronchoscopy in appropriate cases.[7]

The Oncology Department lists care for small-cell and non-small-cell lung cancer, including advanced and metastatic disease, with treatment modalities such as surgery, chemotherapy, targeted therapy, and immunotherapy.[6]

The Chest Surgery Department lists lung cancer surgery including lobectomy, segmentectomy, wedge resection, and pneumonectomy, using minimally invasive techniques where appropriate.[5]

Availability of these options does not mean every treatment is appropriate for every patient. Treatment is selected according to pathology, stage, molecular findings, lung function, overall health, and multidisciplinary review.

Frequently Asked Questions About Lung Cancer Treatment

What is the best treatment for lung cancer?

There is no single best treatment. The plan depends on cancer type, stage, resectability, molecular and immune biomarkers, overall health, and patient preferences.

Can surgery cure lung cancer?

Surgery can form part of curative treatment for selected localized NSCLC, but some patients also require treatment before or after surgery.

Can lung cancer be treated without chemotherapy?

Yes, in some situations. Selected early cancers may be treated with surgery or radiation, while some advanced cancers may be driven by biomarkers that allow targeted therapy. Chemotherapy, however, remains essential in many lung cancer treatment plans.

Which is better, immunotherapy or chemotherapy?

Neither is universally better. Some patients receive immunotherapy alone, others receive immunotherapy with chemotherapy, while others are better treated with targeted therapy or another strategy.

Is targeted therapy suitable for every lung cancer patient?

No. Targeted treatment generally requires a specific molecular alteration that matches an available therapy.

What is PD-L1 testing?

PD-L1 testing measures an immune-related biomarker that can help inform some immunotherapy decisions. It is not the only factor used to select treatment.

Can stage IV lung cancer be treated?

Yes. Treatment options can include targeted therapy, immunotherapy, chemotherapy, radiation, and selected local treatments. The usual aim is disease control, longer survival, symptom relief, and improved quality of life.

Does radiation therapy mean the cancer is terminal?

No. Radiation can be used with curative intent in selected early or locally advanced cancers as well as for control of metastatic disease or symptoms.

Can older adults receive lung cancer treatment?

Yes. Chronological age alone does not determine eligibility. Overall health, organ function, performance status, and treatment goals are more important.

Can the lung cancer treatment plan change over time?

Yes. Treatment may change because of response, side effects, development of resistance, new molecular information, or changes in the patient's overall condition.

Final Thoughts: Understand the Tumor Before Choosing the Treatment

The greatest change in modern lung cancer care is not one treatment becoming stronger than all the others. It is the increasing ability to match treatment to the biology and clinical behavior of each cancer.

One patient may need surgery, another therapy before and after surgery, another targeted therapy for a driver mutation, and another a combination of immunotherapy and chemotherapy.

That is why cancer type, stage, resectability, biomarkers, and patient fitness need to be understood together before treatment is selected.

For complex cases, multidisciplinary decision-making helps combine these factors into one coherent treatment strategy rather than basing treatment on a single scan or specialty.

Medical disclaimer: This article provides general health education and should not be used to select lung cancer medication or treatment. Individual treatment requires specialist assessment, pathology, staging, and appropriate molecular testing.

Medical References

1. National Cancer Institute — Non-Small Cell Lung Cancer Treatment
2. National Cancer Institute — Non-Small Cell Lung Cancer Treatment, Health Professional Version
3. National Cancer Institute — Small Cell Lung Cancer Treatment
4. National Cancer Institute — Biomarker Testing for Cancer Treatment
5. Mouwasat Hospital — Chest Surgery
6. Mouwasat Hospital — Oncology
7. Mouwasat Hospital — Pulmonology
8. Mouwasat Hospital — Published Stage IV Lung Cancer Multidisciplinary Treatment Case

Lung Cancer Stages: What Stages 1 to 4 Mean and Can Lung Cancer Be Cured?

Hearing that lung cancer is “stage III” or “stage IV” can make the stage number feel like a complete prediction of what will happen next. It is not. Cancer stage describes how far the disease has spread; it does not function as a countdown of how long an individual patient will live.

Stage is also different from tumor grade. Stage describes the size and spread of cancer, while grade describes how abnormal the cancer cells appear under a microscope and can provide information about how the cancer may behave.[1]

For non-small cell lung cancer (NSCLC), current classification uses the 9th edition TNM system, which became effective for lung cancer in 2025 and describes the primary tumor, lymph-node involvement, and distant metastasis.[2][3]

If you are looking first for symptoms, risk factors, and how lung cancer is diagnosed, read our complete guide to lung cancer symptoms and early detection.

What Does Lung Cancer Stage Mean?

Cancer stage describes the extent of disease in the body at the time of assessment.

Staging attempts to answer questions such as:

• How large is the primary tumor?
• Has it invaded nearby structures?
• Are regional lymph nodes involved?
• Which lymph-node stations are involved?
• Is there cancer in the opposite lung?
• Is the pleura or pericardium involved?
• Has cancer spread to a distant organ?
• If distant metastases are present, how many are there and how many organ systems are involved?

Stage is essential for treatment planning and prognosis, but it is not the only information that matters.

What Is the Difference Between Stage and Grade?

NCI specifically distinguishes tumor grade from cancer stage.[1]

When people use the phrase “grade 4 lung cancer,” they often actually mean stage IV lung cancer.

How Does the TNM System Work?

T, N, and M are then combined into a stage group such as IA, IIB, IIIA, or IVA.

What Changed in TNM Version 9?

The 9th edition TNM classification for lung cancer took effect in 2025.[2][3]

Important changes include:

• The fundamental T descriptors remained largely unchanged.
• N2 was divided into N2a for a single involved ipsilateral mediastinal/subcarinal nodal station and N2b for multiple involved N2 stations.
• M1c was divided into M1c1 for multiple extrathoracic metastases within one organ system and M1c2 for metastases involving multiple organ systems.
• Some stage-group assignments changed as a result.

The changes provide greater detail about disease burden rather than simply labeling every patient with nodal or metastatic disease in the same way.

What Is Stage 0 Lung Cancer?

Stage 0 refers to carcinoma in situ, where abnormal cancer cells remain highly localized and have not yet developed into more deeply invasive cancer.

It represents the earliest stage and is generally approached with local treatment.

What Is Stage I Lung Cancer?

In stage I NSCLC, cancer remains localized to the lung without regional lymph-node metastasis.

Subgroups within stage I reflect differences in tumor size and local features.

For many medically suitable patients, stage I disease can be treated with curative intent, often with surgery. Effective local treatment can also be considered when surgery is unsuitable.

Because outcomes are generally better when disease is found early, people at sufficiently high risk may benefit from screening before symptoms occur. Read who should have low-dose CT lung cancer screening.

What Is Stage II Lung Cancer?

Stage II includes cancers that are more locally advanced than stage I and may involve a larger tumor, certain local features, or nearby lymph nodes depending on the TNM combination.

Many stage II NSCLCs remain potentially resectable.

However, surgery may be only one component of treatment. Selected patients may require systemic therapy before surgery, after surgery, or both.

For a full explanation of how these choices are made, read our guide to lung cancer treatment.

What Is Stage III Lung Cancer?

Stage III is not one single clinical situation.

It includes IIIA, IIIB, and IIIC disease and can vary substantially in:

• Primary tumor extent.
• Invasion of surrounding structures.
• Lymph-node location.
• Number of involved nodal stations.
• Whether the cancer is surgically resectable.

NCI describes stage IIIA NSCLC as a heterogeneous group ranging from resectable disease to bulky unresectable nodal disease.[4]

This means some patients may undergo surgery as part of multimodality treatment, while others require combinations of chemotherapy, radiation, immunotherapy, or other treatments.

See Lung Cancer Treatment: Surgery, Targeted Therapy and Immunotherapy for the treatment decision pathway.

What Does Stage IV Lung Cancer Mean?

Stage IV means that distant metastatic disease is present.

It does not mean every stage IV cancer has the same disease burden.

Current NSCLC staging divides stage IV into IVA and IVB.[2]

What Is the Difference Between Stage IVA and IVB?

How Is Lung Cancer Staged?

Staging usually combines multiple sources of information rather than relying on one scan.

Depending on the clinical situation, assessment may involve:

• Medical history and physical examination.
• Chest and body CT imaging.
• PET/CT.
• Brain MRI when appropriate.
• Lymph-node sampling.
• Bronchoscopy and biopsy procedures.
• Pathology from surgical resection when surgery is performed.[4]

For more on how imaging, biopsy, pathology, and biomarkers fit together, read our complete lung cancer guide.

What Is the Difference Between Clinical and Pathological Stage?

Clinical stage is the best estimate before treatment using imaging, biopsy, lymph-node assessment, and other available information.

When surgery is performed, pathology can examine:

• The entire resected tumor.
• Surgical margins.
• Removed lymph nodes.
• Microscopic disease that may not have been visible on imaging.

This can provide a more precise pathological stage. NCI notes that pathological staging requires examination of the tumor, resection margins, and lymph-node status.[4]

How Is Small Cell Lung Cancer Staged?

Although TNM information can also be used, SCLC is commonly described using two practical clinical categories:

Limited-stage SCLC

Cancer remains within a limited chest region and may involve nearby mediastinal or supraclavicular lymph nodes.[5]

Extensive-stage SCLC

Cancer has spread beyond the limited-stage region to other parts of the body.[5]

This distinction is important because treatment planning for SCLC differs substantially from NSCLC.

See our lung cancer treatment guide for the differences between NSCLC and SCLC treatment.

Does Stage Alone Determine Lung Cancer Treatment?

No.

Treatment decisions also depend on:

• NSCLC versus SCLC.
• Histologic subtype.
• Resectability.
• Lung and heart function.
• Performance status.
• Other health conditions.
• Actionable molecular alterations.
• Immune biomarkers such as PD-L1 when clinically relevant.

This is why two patients described as having “stage IV NSCLC” may receive completely different systemic treatments.

Read Lung Cancer Treatment: How Doctors Choose Between Surgery, Targeted Therapy and Immunotherapy for the full treatment decision map.

What Does a 5-Year Survival Rate Mean?

A 5-year relative survival rate does not mean a patient will live for only five years.

Relative survival compares survival among people with a particular cancer with survival among similar people in the general population who do not have that cancer.[1][6]

It is not:

• An expiration date.
• A prediction of one person's exact life expectancy.
• The same as a cure rate.

What Are the Current Lung Cancer Survival Rates?

The American Cancer Society currently reports SEER survival data using localized, regional, and distant disease rather than direct AJCC stage I–IV categories.[6]

The current NSCLC figures are based on people diagnosed from 2015 through 2021, while the SCLC figures use patients diagnosed from 2012 through 2018.[6]

What Do Saudi Lung Cancer Data Show?

Local data provide important context.

The Saudi Cancer Registry 2023 recorded 666 newly diagnosed lung cancer cases among Saudi nationals. More than half—56.8%—were diagnosed with distant-stage disease, while approximately 30.6% were localized at diagnosis.[7]

The Saudi Health Council also states that 5-year survival may reach approximately 70% when lung cancer is detected and treated early and falls to around 30% when disease has reached the lymph nodes.[8]

These local figures should not be combined mathematically with the SEER table because the populations, sources, and staging frameworks differ.

For people at increased risk, screening before symptoms appear can be important. Read our LDCT lung cancer screening guide.

Why Can't Survival Statistics Predict One Person's Outcome?

NCI explains that prognosis is affected by factors including cancer type, stage, grade, tumor characteristics, age, general health, and treatment response.[1]

For lung cancer, additional factors may include:

• NSCLC versus SCLC.
• Histologic subtype.
• Pattern and volume of metastatic disease.
• Performance status.
• Actionable molecular alterations.
• Immune biomarkers.
• Response and tolerance to treatment.

Survival statistics also necessarily look backward because several years are required to calculate long-term outcomes.

ACS specifically notes that people diagnosed today may have a better outlook than historical survival numbers indicate because treatment continues to improve.[6]

Is There Hope With Stage IV Lung Cancer?

Yes, treatment options exist, although stage IV remains advanced cancer.

Treatment commonly aims to:

• Control cancer for as long as possible.
• Extend survival.
• Reduce symptoms and complications.
• Maintain quality of life.

Some patients experience prolonged responses to targeted therapy, immunotherapy, or other modern treatments when the biology of their cancer makes those treatments effective.

To understand why molecular testing can dramatically change stage IV treatment, read our lung cancer treatment guide.

A published Mouwasat Hospital Madinah stage IV lung cancer case describes the use of biopsy, genetic and immune testing, multidisciplinary review, and personalized systemic treatment, followed by a major clinical response.[9]

One patient's response is not a survival estimate or cure rate for other patients with stage IV disease.

Lung Cancer Staging at Mouwasat Hospital

Lung cancer staging can require collaboration among Pulmonology, Radiology, Pathology, Oncology, and Chest Surgery.

The Pulmonology Department at Mouwasat Hospital lists lung cancer diagnosis and staging in collaboration with Oncology, along with bronchoscopic biopsy procedures in appropriate patients.

The Oncology Department treats both NSCLC and SCLC, while the Chest Surgery Department can participate in assessment of surgically resectable disease.

Multidisciplinary review allows the team to combine:

• Disease stage.
• Pathology.
• Resectability.
• Molecular and immune biomarkers.
• Lung function.
• Overall patient health.

Frequently Asked Questions About Lung Cancer Stages

What is the most advanced stage of lung cancer?

Stage IV is the most advanced stage because distant metastasis is present. However, stage IV itself includes different patterns and amounts of metastatic disease.

Is grade 4 lung cancer the same as stage 4?

No. Stage describes how far cancer has spread, while grade describes how abnormal the cells appear under a microscope. People saying “grade 4” often mean stage IV.

Can stage I lung cancer be cured?

Many stage I NSCLCs can be treated with curative intent, particularly when the cancer is localized and effective surgery or another definitive local treatment is possible.

Can stage II lung cancer be cured?

Some stage II cancers can be treated with curative intent. Treatment may include surgery plus systemic therapy before or after surgery depending on the individual cancer.

Is stage III lung cancer treatable?

Yes. Stage III is highly heterogeneous. Some cancers are approached with surgery as part of multimodality treatment, while others are treated with combinations of chemotherapy, radiation, immunotherapy, or other strategies.

Does stage IV mean someone will die soon?

No exact time can be determined from stage alone. Stage IV means distant disease is present, but it does not provide an individual life expectancy.

How long can someone live with stage IV lung cancer?

There is no single answer. Tumor subtype, biomarkers, metastatic pattern, overall health, and treatment response can lead to substantially different outcomes.

Can lung cancer stage change after surgery?

Yes. Surgical pathology can reveal microscopic tumor or lymph-node findings that were not visible before surgery, leading to a more accurate pathological stage.

Does a 5-year survival rate mean I have five years to live?

No. It is a population statistic, not a time limit for an individual patient.

Does finding lung cancer earlier improve outcomes?

In general, localized lung cancer has substantially better outcomes than distant disease, which is why appropriate screening of higher-risk people can be valuable.

Final Thoughts: Stage Describes the Disease, Not the Patient's Entire Future

Lung cancer stage is essential because it describes disease extent and helps guide treatment, but the stage number alone cannot answer every question about treatment or survival.

Stages I through IV are not simply four levels of severity. Stage III and stage IV in particular contain very different clinical patterns.

Prognosis also depends on cancer subtype, biomarkers, disease burden, general health, and response to treatment.

Within this lung cancer cluster:

• Lung Cancer: Symptoms, Risk Factors and Early Detection explains symptoms, risk, and diagnosis.
• Lung Cancer Screening and LDCT explains who may benefit from screening.
• Lung Cancer Treatment explains how stage, biomarkers, surgery, targeted therapy, and immunotherapy shape treatment decisions.

Medical disclaimer: This article is intended for general health education. An individual's prognosis should be discussed using their specific diagnosis, stage, tumor biology, general health, and treatment response rather than population statistics alone.

Medical References

1. National Cancer Institute — Understanding Cancer Prognosis
2. International Association for the Study of Lung Cancer — Staging Cards in Thoracic Oncology, 9th Edition
3. IASLC — Lung Cancer TNM Classification, 9th Edition
4. National Cancer Institute — Non-Small Cell Lung Cancer Treatment and Staging
5. National Cancer Institute — Small Cell Lung Cancer Stages and Treatment
6. American Cancer Society — Lung Cancer Survival Rates
7. Saudi Health Council — Saudi Cancer Registry 2023
8. Saudi Health Council — Lung Cancer
9. Mouwasat Hospital — Published Stage IV Lung Cancer Case